The Hormone
Replacement Therapy (HRT) market is estimated to represent a global market
of USD 15.8 billion by 2017 with growth rate of 7.5%.
Market
Dynamics
Menopause is a natural and inevitable event,
defined as the final menstrual period. It requires a retrospective clinical
diagnosis with ethnic and regional variations. Hormone replacement therapies
(HRT) such as systemic estrogen (skin patch, gel, or cream) are considered to
be the most effective treatment option in the treatment of menopausal night
sweats and hot flashes. These therapies also ease vaginal symptoms of menopause
such as itching, burning, and dryness. Due to this fact, women undergoing these
therapies has increased considerably over the past few years.
As per the Rose Research Survey (April 2014),
women accepting HT therapy has increased considerably, from 4.5 million in 2005
to around 5.0 million in 2014. In addition to this, the growth of this market
is attributed to the rise in a number of women in menopausal age coupled with
growing patient awareness. For example, according to the International
Menopause Society, thousands of women reach menopause experience every day. On
another hand, the high cost of therapies coupled with the high risk of adverse
reactions posing a potential threat to this industry. For example, as per the
study published in PLOS One journal in 2014, testosterone therapy in cardiac
patients considerably increase the risk of heart attack.
Replacement
Therapy Takeaway
In terms of replacement therapy, the market
is categorized as Estrogen, Human Growth Hormone, Testosterone and Thyroid.
Estrogen replacement therapy recorded USD 9.58 billion and is expected to soar
owing to the approval of new products by the United States Food and Drug
Association under this category. Some of the recommended estrogen doses for
women with Primary Ovarian Insufficiency (POI) are 1.25 mg conjugated equine
estrogen (CEE), 17b-estradiol 2 mg/day, and transdermal estradiol 75–100
mg/day.
Furthermore, Climara, Estradot, Divigel,
Elestrin, and EstroGel are some of the commercially available transdermal
estrogen products in the U.S. and Canada market by various manufacturers. On
contrary, thyroid replacement therapy is considered to be the lowest revenue
generating segment and is also pegged to register slowest growth rate i.e. 6.9%
in terms of value. Levothyroxine (generic form of thyroxine) is a most commonly
prescribed thyroid hormone replacement drug across the globe.
Key
Vendor Takeaway
Companies such as Novo Nordisk, Amgen, Inc.,
Abbott, Eli Lily and Genentech are covered under research study. The industry
experiences a high level of competition. In such fragmented landscape, key
players are actively engaged in strategic collaborations to expand their market
presence. For instance, in February 2015, Mylan Laboratories signed an
agreement for the acquisition of Famy Care.
This acquisition has helped the company to
increase its female health product portfolio inclusive of production of hormone
replacement drugs, Intra-Uterine Devices (IUD), and contraceptives. Likewise,
in December 2014, Pfizer collaborated with OPKO Health. As per the agreement,
OPKO would be developing and marketing long-acting human growth hormone
(hGH-CTP) (PF-06836922), whereas Pfizer would take care of the post-market
studies and development costs.
The market size and forecast for each segment
and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research
Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The
scope of this report covers the market by its major segments, which include as
follows:
MARKET,
BY REPLACEMENT THERAPY
Estrogen
Human Growth Hormone
Testosterone
Thyroid
MARKET,
BY ROUTE OF ADMINISTRATION
Parenteral
Oral
Transdermal
Other
MARKET, BY DISEASE
Male Hypogonadism
Menopause
Hypothyroidism
Growth Hormone Deficiency
Others
MARKET,
BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
No comments:
Post a Comment